{"abstract":"The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled \"Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling.\" This guidance is intended to assist the pharmaceutical industry and other investigators engaged in new drug development in evaluating how variations in the human genome, specifically DNA sequence variants, could affect a drug's pharmacokinetics (PK), pharmacodynamics (PD), efficacy, or safety. The guidance provides recommendations on when and how genomic principles should be considered and applied in early-phase clinical studies to address questions arising during drug development and regulatory review.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/01/28/2013-01638.html","cfr_references":[],"citation":"78 FR 5816","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Submit either electronic or written comments on Agency guidances at any time.","disposition_notes":null,"docket_ids":["Docket No. FDA-2011-D-0082"],"dockets":[],"document_number":"2013-01638","effective_on":null,"end_page":5817,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/01/28/2013-01638.xml","html_url":"https://www.federalregister.gov/documents/2013/01/28/2013-01638/guidance-for-industry-on-clinical-pharmacogenomics-premarket-evaluation-in-early-phase-clinical","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-01638?publication_date=2013-01-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-01-28/2013-01638/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":1903,"last_updated":"2026-11-22 08:15:04 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-01-28/pdf/2013-01638.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-01638.pdf?1359122118","publication_date":"2013-01-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/01/28/2013-01638.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2011-D-0082","supporting_documents_count":0,"docket_id":"FDA-2011-D-0082","regulation_id_number":null,"title":"Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability","checked_regulationsdotgov_at":"2019-10-23T03:00:08Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":5816,"subtype":null,"title":"Guidance for Industry on Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling; Availability","toc_doc":"Clinical Pharmacogenomics; Premarket Evaluation in EarlyPhase Clinical Studies and Recommendations for Labeling","toc_subject":"Guidance for Industry; Availability:","topics":[],"type":"Notice","volume":78}